CNS Pharmaceuticals Inc. (NASDAQ:CNSP) saw an upside of 42.62% to close Tuesday at $1.74 after adding $0.52 on the day. The 5-day average trading volume is 835,000 shares of the company’s common stock. It has gained $1.9000 in the past week and touched a new high 2 times within the past 5 days. An average of 290,115 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 210,836.
CNSP’s 1-month performance is -19.07% or -$0.4200 on its low of $1.2000 reached on 08/21/23. The company’s shares have touched a 52-week low of $0.61 and high of $8.64, with the stock’s rally to the 52-week high happening on 04/17/23. YTD, CNSP has lost -27.50% or -$0.6600 and has reached a new high 4 times. However, the current price is down -79.86% from the 52-week high price.
Insider Transactions
CNSP stock investors last saw insider trading activity on Aug 16.Priebe Waldemar (10% Owner) most recently sold 10,000 shares at $1.04 per share on Mar 28. This transaction cost the insider $10,400. 10% Owner, Priebe Waldemar, sold 5,000 shares at a price of $1.09 on Mar 27. Then, on Mar 24, 10% Owner Priebe Waldemar sold 5,000 shares at a price of $1.08 per share. This transaction amounted to $5,400.
Valuation Metrics
CNSP stock has a beta of 1.34. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.76.
CNS Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 1.50, with the current ratio over the same period at 1.50. The firm’s gross profit as reported stood at $7000.0 against revenue of $15.27 million.
Earnings Surprise
For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 11.19% to -$4.02 million, while revenue of -$4.93 million was -22.64% off the previous quarter. Analysts expected CNSP to announce -$2.4 per share in earnings in its latest quarter, but it posted -$2.7, representing a -12.50% surprise. EBITDA for the quarter stood at more than -$4.02 million. CNSP stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 4.0 million, with total debt at $0.17 million. Shareholders hold equity totaling $4.2 million.
Let’s look briefly at CNS Pharmaceuticals Inc. (CNSP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 44.94% to suggest the stock is trending Neutral, with historical volatility in this time period at 292.40%.
The stock’s 5-day moving average is $1.6940, reflecting a +1.75% or $0.0300 change from its current price. CNSP is currently trading -15.53% above its 20-day SMA, +74.66% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -18.69% and SMA200 by-70.97%.
Stochastic %K and %D was 24.99% and 24.09% and the average true range (ATR) pointed at 0.2484. The RSI (14) points at 44.07%, while the 14-day stochastic is at 48.80% with the period’s ATR at 0.2254. The stock’s 9-day MACD Oscillator is pointing at -0.1878 and -0.3300 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Ladenburg Thalmann downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for CNSP stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate CNSP as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
